Ingavirin caps. children. 7 years 60mg 7 pc

$9.50

Ingavirin caps. children. 7 years 60mg 7 pc

Quantity:

Description

Composition
Active substance:
1 capsule contains: imidazoliletanamid pentandiovoy acid (vitaglutam) in terms of 100% substance – 60.00 mg.
Excipients:
Lactose monohydrate – 60.00 mg potato starch – 23.72 mg Colloidal silicon dioxide (Aerosil) – 1.47 mg magnesium stearate – 1.47 mg; hard gelatin capsules: titanium dioxide E 171 – 1.0000% yellow iron oxide coloring E 172 – 1.0000% gelatin – up to 100%; Ink composition for logotype: shellac, propylene E 1520, E 171 titanium dioxide.
Description:
Capsules number 4 yellow. On a lid of the capsule coated white logo in the form of rings and the letter “I” within the ring.
Contents of capsules – granules and powder white or nearly white; It allowed the formation of conglomerates, easy break under slight pressure.
Product form:
Capsules of 60 mg.
7 capsules in blisters or in blisters with a perforation of the film, PVC and aluminum foil printed patent.
One contour packaging together with instructions for use placed into the package.
Contraindications
Contraindications
Hypersensitivity to the active ingredient or any other component of the formulation.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Pregnancy.
During breastfeeding.
Children under 7 years old.
This dosage form is not designed for use in individuals 18 years or older (necessary to use dosage forms enabling reception Ingavirin drug in a dose of 90 mg).
Dosage
60 mg
Indications
Indications
Treatment of influenza A and B and other acute respiratory viral infections (adenovirus infection, parainfluenza, Respiro-Tornio syncytial infection) in children aged 7 to 17 years.
Prevention of influenza A and B and other acute respiratory viral infections in children aged 7 to 17 years old ..
Interaction with other drugs
Drug interaction Ingavirin preparation is not described.
Overdose
About the cases of drug overdose Ingavirin it has not yet been reported.
pharmachologic effect
Pharmacodynamics:
Antiviral drug.
In preclinical and clinical studies show efficacy Ingavirin drug against influenza virus type A (A (H1N1), at r. H. “Swine» A (H1N1) pdm09, A (H3N2), A (H5N1)) and type B, adenovirus, parainfluenza virus, respiratory syncytial virus; in preclinical studies: coronavirus, metapneumovirus, enteroviruses, including coxsackie virus and rhinovirus.
Ingavirin drug promotes the accelerated elimination of viruses, reduce the duration of disease, decrease the risk of complications.
The mechanism of action is realized at the level of the infected cells due to stimulation of the innate immune factors, suppressed viral proteins. In experimental studies, in particular, shows that the drug increases Ingavirin interferon receptor IFNAR expression of the first type on the surface of epithelial and immune cells. Increased density interferon receptor leads to increased cell sensitivity to the signals of endogenous interferon. The process is accompanied by the activation (phosphorylation) of the protein-transmitter STAT1, transmitting a signal to the cell nucleus to induce antiviral gene. It is shown that in the conditions of infection, the drug stimulates the production of antiviral effector protein MxA inhibiting intracellular transport ribonucleoproteins different viruses, slowing the process of viral replication.
Ingavirin drug causes an increase in blood interferon to the physiological norm, stimulates and normalizes the reduced alpha interferon producing ability of white blood cells, stimulates the gamma interferon-producing ability of white blood cells. It causes generation of cytotoxic lymphocytes, and increases the content of NK-T cells having a high killer activity against cells infected with viruses.
Anti-inflammatory effect due to suppression of the production of key pro-inflammatory cytokines (tumor necrosis factor (TNF-alpha), interleukin (IL-1beta and IL-6)), a reduction of myeloperoxidase activity.
In experimental studies have shown that the combined use of the drug Ingavirin with antibiotics increases the effectiveness of therapy on bacterial sepsis model, including caused by penicillin-resistant strains of Staphylococcus.
The experimental toxicological studies indicate low toxicity and high safety profile.
The parameters of acute toxicity Ingavirin drug belongs to 4 class of toxicity – “Low-toxic substance” (determining the LD50 experiments on acute toxicity lethal dose could not be determined).
The drug has no mutagenic, immunotoxic, carcinogenic and allergenic properties, has no local irritating action. Ingavirin drug does not affect reproductive function has no embryotoxicity or teratogenicity.
Efficacy in children
In a double-blind, randomized, placebo-controlled, multicenter study to assess the clinical efficacy and safety Ingavirin drug in a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections in 180 children aged 13-17 years, it has been shown that the drug Ingavirin significantly superior to placebo, faster normalizing body temperature kupiruya intoxication, fever, catarrhal phenomena. Double-blind, randomized, placebo-controlled, multicenter study to assess the clinical efficacy and safety Ingavirin drug in a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections in 310 children aged 7-12 years showed that the drug Ingavirin has significantly higher efficiency compared to placebo and provides a rapid (on average 18 hours) reduction in body temperature and the disappearance of intoxication symptoms (sore throat, scratchy, pain on swallowing, nasal congestion, runny).
Pharmacokinetics:
Absorption and distribution.
At recommended dosages definition plasma drug available techniques is not possible. In an experiment using a radioactive label has been established: the drug goes quickly into the bloodstream from the gastrointestinal tract. Uniformly distributed over the internal organs. The maximum concentration in the blood, blood plasma and most organs are reached 30 minutes after drug administration. Values ​​of AUC (area under the curve “concentration -time”), kidney, liver and lung slightly exceed blood AUC (43.77 ug. Hr / g). AUC values ​​for the spleen, adrenal glands, lymph nodes and thymus lower AUC blood. MRT (mean retention time of drugs) in the blood -37.2 hours. During the course taking the drug once a day is its accumulation in internal organs and tissues. In this qualitative characteristics pharmacokinetic curves after administration of each preparation were identical: a rapid increase of drug concentration following each administration over 0.5-1 hour after administration and then slowly decline to 24 hours.
Metabolism.
The drug is not metabolized in the body and is excreted unchanged.
Withdrawal.
Basic elimination process occurs within 24 hours. During this period, output 80% of the dose: 34.8% is excreted in the time interval from 0 to 5 hours and 45.2% in the time interval from 5 to 24 hours. Of these, 77% is excreted through the intestine and 23% – through the kidneys.
Pregnancy and breast-feeding
Use of the drug during pregnancy has not been studied. Use of the drug during lactation has not been studied, therefore, if necessary, use during lactation should stop breastfeeding.
Conditions of supply of pharmacies
Without a prescription.
side effects
Allergic reactions (rare).
special instructions
Not recommended simultaneous reception of other antiviral drugs.
Effects on ability to drive vehicles, mechanisms:
Has not been studied, however, given the mechanism of action and the profile of adverse reactions, it can be assumed that the drug does not affect the ability to drive vehicles, machinery.
Storage conditions
In the dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside. Regardless of the meal.
For treatment of influenza and acute respiratory viral infections for children from 7 to 17 years appoint 1 capsule (60 mg), 1 per day. Duration of treatment 5-7 days (depending on the state of gravity). The drug begins with the onset of symptoms, preferably within 2 days of the onset of the disease.
For the prevention of influenza and acute respiratory viral infections after contact with sick persons for children from 7 to 17 years appoint 1 capsule (60 mg), 1 per day for 7 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Valenta Pharm

There are no reviews yet.

Add your review